The frequency of anti-GRP78 autoantibody was not observed to be significantly different in comparison group in both test group and validation group (tumor size: ≥5 cm vs. <5 cm, lymphatic metastasis: yes vs. no, differentiation: poor vs. moderate and high, and stage: I + II vs. III + IV) (P > 0.05). This evidence concerns the gene HSPA5 and neoplasm.